Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses (Q40880297)

24 September 2017

title

Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses (English)

1 reference

24 September 2017

0 references

Rammensee HG

1 reference

24 September 2017

Speidel K

1 reference

24 September 2017

Osen W

1 reference

24 September 2017

Faath S

1 reference

24 September 2017

Hilgert I

1 reference

24 September 2017

Obst R

1 reference

24 September 2017

Braspenning J

1 reference

24 September 2017

Momburg F

1 reference

24 September 2017

Hämmerling GJ

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 September 1997

1 reference

European Journal of Immunology

24 September 2017

published in

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

2391-2399

1 reference

Immunology: The ins and outs of antigen processing and presentations

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Supply and transport of peptides presented by class I MHC molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Cytotoxic T lymphocytes against a soluble protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4− CD8+ cytotoxic T lymphocytes in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Induction of protective cytotoxic T cells with viral proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Presentation of exogenous antigen with class I major histocompatibility complex molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization aga

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Phagocytic processing of bacterial antigens for class I MHC presentation to T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Injection of detergent-denatured ovalbumin primes murine class I-restricted cytotoxic T cells in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

TAP1-independent loading of class I molecules by exogenous viral proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Selection of highly transfectable variant from mouse mastocytoma P815.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

A human beta-actin expression vector system directs high-level accumulation of antisense transcripts

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Nucleotide sequence of an HLA-A1 gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Synthesis, phosphorylation, and nuclear localization of human papillomavirus E7 protein in Schizosaccharomyces pombe

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

HPV16 E7 phosphorylation in fission yeast: characterization and biological effects

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

A General Purification Protocol for E7 Proteins from “High- and Low-Risk” Human Papillomavirus Types Expressed in the YeastSchizosaccharomyces pombe

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Antigen recognition. Class discrimination in the world of immunology

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Major histocompatibility complex class I-binding peptides are recycled to the cell surface after internalization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Adjuvants: current status, clinical perspectives and future prospects

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830270938

7 January 2021

Identifiers

DOI

10.1002/EJI.1830270938

1 reference

24 September 2017

1 reference